Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)
PRESAGE
1 other identifier
observational
1,080
1 country
1
Brief Summary
seroPREvalence vis-à-vis SARS-CoV2 and correlation with clinical forms of COVID-19 in patients followed in Pulmonology in the cluster area of the Grand-Est region.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2020
CompletedFirst Posted
Study publicly available on registry
August 27, 2020
CompletedStudy Start
First participant enrolled
September 4, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedJanuary 27, 2021
September 1, 2020
2.2 years
August 25, 2020
January 26, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Determine and compare the seroprevalence for SARS-CoV2 among patients with respiratory pathologies monitored in Pneumology at the Strasbourg University Hospital, in the cluster zone of the Grand Est.
Carrying out a serological assay of specific antibodies to SARS-CoV-2
15 months
Eligibility Criteria
Patient followed in pulmonology at Strasbourg University Hospital
You may qualify if:
- Man or woman from 18 years old and without upper age limit
- Patient followed in pulmonology at Strasbourg University Hospital
- Patient presenting at least one of the following pathologies:
- severe persistent asthma (200 patients)
- chest cancer that is active or has received treatment within a period of less than one year (300 patients)
- history of lung transplantation performed before the start of the epidemic (02/29/2020) (300 patients)
- idiopathic or other diffuse interstitial lung disease, sarcoidosis or vasculitis (70 patients)
- pulmonary arterial hypertension (PAH) (group 1 of the international classification) any cause or chronic thromboembolic PAH (group 4): (60 patients)
- Severe COPD in the respiratory failure stage (150 patients)
- Subject affiliated to a social health insurance protection scheme
- Subject able to understand the objectives of the research
- Subject having signed an informed consent
You may not qualify if:
- Inability to provide informed information about the subject (subject in an emergency situation, difficulty in understanding the subject, etc.)
- Subject under safeguard of justice
- Subject under guardianship or guardianship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, Bas-Rhin, 67091, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Céline MASCAUX
CHU de Strasbourg
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 25, 2020
First Posted
August 27, 2020
Study Start
September 4, 2020
Primary Completion
December 1, 2022
Study Completion
December 1, 2022
Last Updated
January 27, 2021
Record last verified: 2020-09